AI10 Stock Overview
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biofrontera Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$2.18 |
| 52 Week Low | US$0.69 |
| Beta | 0.51 |
| 11 Month Change | -10.17% |
| 3 Month Change | -22.06% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 12.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| AI10 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.8% |
| 1Y | n/a | -18.4% | 9.1% |
Return vs Industry: Insufficient data to determine how AI10 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AI10 performed against the German Market.
Price Volatility
| AI10 volatility | |
|---|---|
| AI10 Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AI10's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AI10's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 84 | Hermann Luebbert | www.biofrontera-us.com |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Biofrontera Inc. Fundamentals Summary
| AI10 fundamental statistics | |
|---|---|
| Market cap | €5.41m |
| Earnings (TTM) | -€12.23m |
| Revenue (TTM) | €33.69m |
0.2x
P/S Ratio-0.5x
P/E RatioIs AI10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AI10 income statement (TTM) | |
|---|---|
| Revenue | US$35.36m |
| Cost of Revenue | US$18.70m |
| Gross Profit | US$16.66m |
| Other Expenses | US$29.49m |
| Earnings | -US$12.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 47.10% |
| Net Profit Margin | -36.31% |
| Debt/Equity Ratio | 0% |
How did AI10 perform over the long term?
See historical performance and comparison